The Roche Cobas Amplicor MTB assay, recently replaced by the Roche Cobas TaqMan MTB assay, was one of the first commercially available assays for detection of the Mycobacterium tuberculosis complex based on nucleic acid amplification. We reported previously on the limited specificity of the Cobas Amplicor MTB assay, in particular for positive samples with an optical density at 660 nm (OD 660 ) of <2.0. Using a selected set of respiratory samples, which were scored as false positive by the Cobas Amplicor test, we demonstrate here that the specificity of the Cobas TaqMan assay is significantly improved. In addition, our study of a set of 133 clinical samples revealed that the Cobas TaqMan MTB assay showed significantly less PCR inhibition than the Cobas Amplicor test. An overall concordance of 98.2% was observed between the two assays. In a subsequent prospective study, we evaluated the performance of the Roche Cobas TaqMan MTB assay on 1,143 clinical specimens, including respiratory (n ‫؍‬ 838) and nonrespiratory (n ‫؍‬ 305) specimens. Using culture as the gold standard, we found a sensitivity of 88.4% and a specificity of 98.8% for the 838 respiratory specimens, compared to a sensitivity of 63.6% and a specificity of 94.6% for the 305 nonrespiratory specimens. We conclude that the Cobas TaqMan MTB assay is a significantly improved tool for the direct detection of M. tuberculosis DNA in clinical specimens. The Cobas Amplicor test is based on amplification of a 584-bp 5= part of the 16S rRNA gene (1, 2) using biotinylated primers, a capture probe, and photometric staining for quantification (3, 4). The Cobas Amplicor test was extensively evaluated for various clinical specimens and demonstrated high sensitivity and specificity, in particular for smear-positive samples (5). We reported previously on a substantial rate of false-positive samples, in particular when the Cobas Amplicor MTB test showed results with optical density at 660 nm (OD 660 ) values of Ͼ0.35 and Ͻ2.0 (6). The observed false-positive results were demonstrated to be due to cross-reactivity of the capture probe with closely related species, such as nontuberculous mycobacterial species and Corynebacterium spp. (6).
D
irect detection of Mycobacterium tuberculosis complex DNA from clinical specimens has become an important part of diagnostic mycobacteriology. PCR-based assays detect DNA that can originate from living or dead cells. The clinical interpretation of M. tuberculosis complex DNA detection is dependent on the patient's clinical data and complementary laboratory data, such as smear microscopy and culture. Several commercial tests have been introduced during the past few years, for example, the Cobas Amplicor M. tuberculosis (MTB) PCR test (Roche Diagnostics, Rotkreuz, Switzerland), the Gen-Probe Amplified M. tuberculosis direct (MTD) test (Gen-Probe, Inc., San Diego, CA), and the BD ProbeTec direct system (Becton Dickinson, Sparks, MD).
The Cobas Amplicor test is based on amplification of a 584-bp 5= part of the 16S rRNA gene (1, 2) using biotinylated primers, a capture probe, and photometric staining for quantification (3, 4) . The Cobas Amplicor test was extensively evaluated for various clinical specimens and demonstrated high sensitivity and specificity, in particular for smear-positive samples (5) . We reported previously on a substantial rate of false-positive samples, in particular when the Cobas Amplicor MTB test showed results with optical density at 660 nm (OD 660 ) values of Ͼ0.35 and Ͻ2.0 (6). The observed false-positive results were demonstrated to be due to cross-reactivity of the capture probe with closely related species, such as nontuberculous mycobacterial species and Corynebacterium spp. (6) .
Recently, Roche Diagnostics (Rotkreuz, Switzerland) replaced the Cobas Amplicor MTB test with the Cobas TaqMan MTB test. The Cobas TaqMan MTB test is a real-time PCR assay that amplifies part of the 16S rRNA gene with the use of a TaqMan probe for the detection of Mycobacterium tuberculosis complex DNA in clinical specimens (7) . Here, we evaluated the Cobas TaqMan MTB assay and compared its performance with that of the Cobas Amplicor MTB assay. In a prospective study, we analyzed the performance of the Cobas TaqMan MTB assay for routine mycobacteriology laboratory use during a 6-month period in which 1,143 specimens were submitted for MTB PCR testing. taminated samples (0.5 ml) by using a respiratory specimen preparation kit (Roche Diagnostics) (4). According to the manufacturer, the Cobas Amplicor MTB test is considered valid if the optical density at 660 nm (OD 660 ) of the positive control is Ͼ2.0 and the OD 660 of the negative control is Ͻ0.25. A specimen is scored positive for M. tuberculosis if the OD 660 is Ն0.35. A sample is scored negative for M. tuberculosis if the OD 660 of the sample is Ͻ0.35 and the OD 660 of the internal inhibition control is Ն0.35 (4). For the Cobas TaqMan assay, a sample was interpreted as positive when a crossing point (CP) was registered at Ͻ45 (7).
Amplification, DNA purification, and sequencing of positive samples and cultures. Samples that were scored positive in the Cobas Amplicor MTB assay with OD 660 values of Ն0.35 and Ͻ2.0 were subjected to PCR-mediated 16S rRNA gene sequence analysis. For gene amplification, the Cobas Amplicor pan-Mycobacterium primers KY18 (5=-CAC ATG CAA GTC GAA CGG AAA GG-3=) and KY75 (5=-GCC CGT ATC GCC CGC ACG CTC ACA-3=) or primers 283 and 264 were used in separate PCRs as described previously (9, 10) . PCR products were sequenced using the primer Mbakt-14 (5=-GRG RTA CTCGAG TGG CGA AC-3=) (11) . If unsatisfactory PCR or sequencing results were obtained, reamplification was done with primers KY18 and 259 or primers 283 and 259 (2, 9) . Amplicons with CPs of Ͼ45 or maximum curve values of Ͻ0.5 by the Cobas TaqMan MTB assay were purified using a PCR purification kit (Qiagen, Hombrechtikon, Switzerland) and subjected to sequencing using the primer Mbakt-14.
Sequences were analyzed using SmartGene IDNS software and databases (SmartGene, Zug, Switzerland). Homology analysis and species identification were carried out as described previously (9, 12, 13) . Sequencing of 16S rRNA genes from cultures was performed using the primers 283 and 264 for PCR amplification and the primer Mbakt-14 for sequencing (10) . In the case of Mycobacterium chelonae complex identification, sequence analysis of rpoB (14) was used for species assignment, e.g., to M. massiliense, M. bolletii, M. abscessus, or M. chelonae. In the case of M. kansasii/M. gastri identification, sequence analysis of hsp65 was used for differentiation (15) .
RESULTS
Retrospective testing of clinical specimens categorized as false positive by the Cobas Amplicor MTB assay. We studied 11 clinical respiratory specimens (collected from 11 patients in 2009) which were scored positive by the Cobas Amplicor assay (OD 660 s, Ͼ0.350 and Ͻ1.5) ( Table 1) . As determined by 16S rRNA gene sequencing, five of these samples showed the presence of Corynebacterium spp., one sample showed the presence of the M. chelonae complex, and the remaining 5 samples produced DNA sequences of low quality, which did not allow species identification. On the basis of 16S rRNA gene sequencing and homology analysis, microscopy, cultural recovery, and clinical data, these samples were categorized as false positive by the Cobas Amplicor assay. All samples were scored negative by the Cobas TaqMan MTB test (Table 1) .
Comparative analysis of the Cobas Amplicor MTB and Cobas TaqMan MTB assays. The 133 clinical specimens received in the routine diagnostic laboratory for testing for the presence of the Mycobacterium tuberculosis complex were subjected in parallel to the Cobas Amplicor and Cobas TaqMan assays ( Table 2) . Clinical samples (n ϭ 133) consisted of 100 respiratory specimens (sputum, n ϭ 52; tracheal bronchial aspirate, n ϭ 24; and bronchial alveolar lavage fluid, n ϭ 24) and 33 nonrespiratory specimens (biopsy, n ϭ 10; urine, n ϭ 8; pleura aspirate, n ϭ 7; ascites, n ϭ 2; a Clinical samples (n ϭ 112) consisted of 82 respiratory specimens (sputum, n ϭ 43; bronchial alveolar lavage fluid, n ϭ 20; and tracheal bronchial aspirate, n ϭ 19) and 30 nonrespiratory specimens (urine, n ϭ 8; pleura aspirate, n ϭ 7; biopsy, n ϭ 7; ascites, n ϭ 2; cerebrospinal fluid [CSF], n ϭ 2; ear swab, n ϭ 1; aspirate, n ϭ 1; catheter drainage, n ϭ 1; and deep wound swab, n ϭ 1). The eight samples that were positive in both the Cobas Amplicor and Cobas TaqMan assays were respiratory (n ϭ 6), deep wound swab (n ϭ 1), and CSF (n ϭ 1) specimens. The two false-positive samples in the Cobas Amplicor assay were both respiratory specimens. b False positives by Cobas Amplicor MTB. c A total of 112 samples not inhibited for PCR were eligible for this analysis.
cerebrospinal fluid, n ϭ 2; ear swab, n ϭ 1; aspirate, n ϭ 1; catheter drainage, n ϭ 1; and deep wound swab, n ϭ 1). Twenty-one of the 133 samples (respiratory, n ϭ 18; and biopsy, n ϭ 3) showed inhibition of the PCRs (i) by both assays (n ϭ 6), (ii) by the Cobas Amplicor assay only (n ϭ 12), or (iii) by the Cobas TaqMan assay only (n ϭ 3). One tracheal bronchial aspirate showed inhibition of the PCR by the Cobas Amplicor assay but was scored positive by the Cobas TaqMan assay. Sequencing of the amplicon generated by the Cobas TaqMan assay revealed the presence of M. tuberculosis complex DNA. The sample was smear negative but culture positive for M. tuberculosis, confirming the positive result from the Cobas TaqMan assay. The remaining clinical samples that showed inhibition (n ϭ 20) were all scored negative for M. tuberculosis by culture.
The 112 noninhibited specimens (82 respiratory and 30 nonrespiratory) were eligible for analysis of concordance between the Cobas Amplicor and the Cobas TaqMan assays (Table 2) . Two sputum specimens, which were scored positive for M. tuberculosis by the Cobas Amplicor assay (OD 660 s, 0.597 and 0.643, respectively) and negative by the Cobas TaqMan assay, were evaluated in further detail. Sequence analysis of the PCR amplicon showed the presence of Mycobacterium massiliense in one sample and Corynebacterium pseudodiphtheriticum in the second sample; these samples were smear and M. tuberculosis culture negative. From these two patients, a total of 5 samples were evaluated, none of which was positive by culture or PCR for M. tuberculosis. Evaluation of the patients' clinical histories did not reveal any sign of M. tuberculosis infection. As a result, both samples were judged to be false positive by the Cobas Amplicor assay. Eight samples were positive in both the Cobas Amplicor and the Cobas TaqMan assays; all had OD 660 values of Ͼ2.0 in the Cobas Amplicor assay. The 8 M. tuberculosis-positive samples included 6 respiratory, 1 deep wound swab, and 1 CSF sample. The overall agreement between the Cobas Amplicor and Cobas TaqMan assay results (n ϭ 112) was 98.2%, with a positive agreement of 80% and a negative agreement of 100% (Table 2) .
Prospective evaluation of the Cobas TaqMan MTB assay in the routine mycobacteriology laboratory. Over a period of 6 months, 1,143 respiratory and nonrespiratory clinical samples submitted to the routine mycobacteriology laboratory were tested for the presence of M. tuberculosis DNA in a prospective study design. Inhibition of the PCR, as indicated by a negative internal control as used in the M. tuberculosis assay, occurred for 34 (3.0%) of the specimens. None of the PCR-inhibited samples was smear positive and/or M. tuberculosis culture positive. A negative PCR result was obtained for 1,011 (88.5%) of the specimens. Ninetyeight (8.5%) samples tested positive by the Cobas TaqMan M. tuberculosis assay. Seventy-five of the 98 specimens were positive for M. tuberculosis with MTB PCR and culture, and 52 of these specimens were smear microscopy positive. Twenty-three of the 98 MTB PCR-positive specimens were M. tuberculosis culture negative, of which 7 were smear microscopy positive (Tables 3 and 4) . Evaluation of the patients' clinical histories showed that all 23 culture-negative specimens were finally categorized as true positives for the detection of M. tuberculosis DNA ( Table 4 ). The 23 specimens were collected from 13 patients who had a clinical history of tuberculosis. For 12 of the 13 patients, at least one positive M. tuberculosis culture was grown from another sample. For 1 of the 13 patients (Table 4 , specimen no. 20), no positive culture was registered. However, this patient had undergone a Mycobacterium bovis BCG instillation for bladder carcinoma treatment and showed clinical symptoms of disseminated tuberculosis.
Ninety-one specimens were M. tuberculosis culture positive, and 16 of them (sputum, n ϭ 4; aspirate, n ϭ 3; lymph node, n ϭ 3; tracheal bronchial aspirate, n ϭ 2; bronchial aspirate, n ϭ 2; gastric fluid, n ϭ 1; and ascites, n ϭ 1) were negative by MTB PCR testing. None of these 16 specimens was smear microscopy positive.
Since all specimens were analyzed for culture, we used this parameter as the gold standard for the calculation of sensitivity and specificity. Overall, we determined a sensitivity of 82.4% and a specificity of 97.7% for the Cobas TaqMan MTB assay ( Table 3) .
The overall sensitivity of the Cobas TaqMan MTB assay for microscopy smear-positive samples was 100% and for smear-negative samples was 73.6%.
The 1,143 clinical specimens consisted of 838 respiratory samples (sputum, n ϭ 501; tracheal bronchial aspirate, n ϭ 181; bronchial alveolar lavage fluid, n ϭ 139; bronchial aspirate, n ϭ 8; and others, n ϭ 9) and 305 nonrespiratory specimens (aspirate, n ϭ 102; tissue, n ϭ 78; urine, n ϭ 27; cerebrospinal fluid (CSF), n ϭ 23; biopsy, n ϭ 9; wound swab, n ϭ 12; lymph node, n ϭ 11; gastric fluid, n ϭ 9; bone marrow, n ϭ 9; ascites, n ϭ 6; abscess, a These specimens were all from patients who had a clinical history of tuberculosis (see Table 4 ). Accordingly, the specificity of Cobas TaqMan MTB is to be calculated as 100%.
n ϭ 5; stool, n ϭ 5; blood EDTA, n ϭ 4; nonspecified, n ϭ 3; bone, n ϭ 1; and ejaculate, n ϭ 1) ( Table 5) . Nine of the 838 (1.1%) respiratory samples, which were all sputum specimens, were inhibited for PCR. Seven hundred fiftynine of the 829 noninhibited specimens were MTB PCR negative, and 70/829 were MTB PCR positive. Using culture results as the gold standard, we found a sensitivity of 88.4% and a specificity of 98.8% for respiratory specimens (Table 3) . Twenty-five of the 305 (8.2%) nonrespiratory samples (tissue, n ϭ 12; bone marrow, n ϭ 4; stool, n ϭ 3; abscess, n ϭ 1; blood EDTA, n ϭ 1; CSF, n ϭ 1; lymph node, n ϭ 1; gastric fluid, n ϭ 1; and aspirate, n ϭ 1) were inhibited for PCR (Table 5) . Two hundred fifty-two of the 280 noninhibited specimens were MTB PCR negative, and 28/280 were MTB PCR positive. Using culture as the gold standard, we found a sensitivity of 63.8% and a specificity of 94.6% for nonrespiratory specimens (Table 3) .
DISCUSSION
PCR-based tests allow rapid and reliable laboratory detection of M. tuberculosis DNA, which is crucial for early diagnosis and clinical management and for proper therapy. If there is a suspicion of tuberculosis on the basis of the clinical data, it is recommended that three clinical samples be submitted to the diagnostic laboratory for smear microscopy, culture, and, preferably, MTB PCR analyses. The Cobas Amplicor MTB test is commonly regarded as a reliable assay for the majority of specimens tested (16, 17, 18) . However, we previously reported on a substantial rate of falsepositive results for OD 660 values of Ͻ2.0 (6).
The limited specificity was corroborated by an additional 11 specimens that were identified in our routine diagnostic laboratory in 2009 and categorized as false positives based on microscopy, cultures, results of other patients' specimens, and evaluation of the patients' clinical histories (Table 1) . Roche recently replaced the Cobas Amplicor MTB test with the Cobas TaqMan MTB test. We initially studied the 11 selected patient specimens that were scored false positive with the Cobas Amplicor MTB test. A significantly increased specificity was found, as all 11 samples tested negative with the Cobas TaqMan assay (Table 1) .
To comparatively analyze the Cobas Amplicor and Cobas TaqMan MTB tests, a set of 133 clinical samples randomly obtained from our routine diagnostic workflow, consisting of 82 respiratory and 30 nonrespiratory specimens, were tested in both assays. A 50% reduction in the number of specimens for which PCR was inhibited was observed using the Cobas TaqMan MTB test (9/133 inhibited) in comparison with the Cobas Amplicor MTB test (18/ 133 inhibited). Since samples were tested in parallel using the same nucleic acid extract, this can be explained only by differences in test conditions. Of note, one of these specimens tested positive by the Cobas TaqMan assay. Analysis of the results of the 112 eligible samples showed a concordance of 98.2% (Table 2) . Two respiratory samples scored positive in the Cobas Amplicor MTB test and negative in the Cobas TaqMan MTB assay (Table 2) . In-depth analyses of these samples combined with the patients' clinical histories categorized the two samples as false positives.
In a prospective study design, we evaluated the Cobas MTB TaqMan assay for clinical samples (n ϭ 1,143), respiratory and nonrespiratory, submitted to the routine mycobacteriology laboratory for M. tuberculosis PCR testing (Tables 3, 4 , and 5). The results showed a 97.7% specificity for detection of M. tuberculosis using culture as the gold standard (Table 3) . However, analysis of the data from all 13 patients with specimens (n ϭ 23) that produced culture-negative and PCR-positive results showed a clinical history of tuberculosis; thus, the specificity of the Cobas TaqMan MTB assay is higher than 97.7%. The Cobas MTB TaqMan test was developed primarily for respiratory specimens. However, we also analyzed a substantial set of nonrespiratory specimens (Table  5) , the results of which showed that this assay is also suitable for such samples (Table 3) . With culture as the gold standard, the sensitivity for respiratory specimens (88.4%) was significantly higher than that for nonrespiratory samples (63.6%) ( Table 3) . Inhibition of PCR was more frequently observed for nonrespiratory samples (8.2%) than for respiratory samples (1.1%). Reduced sensitivity and increased PCR inhibition in nonrespiratory samples, such as stool, bone marrow, tissue, and blood, is presumably due to a diverse range of PCR inhibitors (19) . In addition, unequal distribution of bacterial cells is more likely to occur in nonrespiratory specimens, such as tissue, than in respiratory samples. Overall, based on patients' clinical histories, the MTB PCR performed well in comparison to culture (for a detailed comparison on the basis of single-specimen analysis, see Table 3 ).
In general, the results found in this study are in line with those of recently published studies on the performance of the Cobas TaqMan assay (20, 21, 22, 23, 24, 25, 26) . However, those studies were restricted mostly to respiratory samples, discrepant test results were not analyzed in detail, and sequence analysis of the amplicon was not used for validation of the test results.
In conclusion, the specificity of the Cobas TaqMan MTB test is significantly improved over that of the Cobas Amplicor MTB test, and the number of observed PCR inhibitions was reduced by 50% using the Cobas TaqMan assay. Another advantage of the Cobas TaqMan assay is the possibility of direct sequencing of the PCR amplicon following a relatively simple purification step. The sequence of the amplicon containing hypervariable regions A and B of the 16S rRNA gene (9) allows for the accurate identification of M. tuberculosis in the case of doubtful or borderline test results.
